- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00769171
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections) (DRAGON)
December 17, 2014 updated by: Bayer
A Prospective, Randomized, Double-blinded, Multi-center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidazole 500mg Every 12h for the Treatment of Patients With Complicated Intra-abdominal Infections
The purpose of this study is to assess the safety and efficacy of intravenous administration Moxifloxacin (BAY 12-8039) compared to intravenous ceftriaxone and metronidazole for the treatment of patients with complicated intra abdominal infections.
In view of the fact that intra abdominal infections are typically polymicrobial and are often treated empirically, the selected antibacterial agent must cover the likely spectrum of bacterial pathogens.
Combination antibiotics therapy has been widely used with great success.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
364
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
-
Beijing, China, 100044
-
Beijing, China, 100050
-
Beijing, China, 100730
-
Shanghai, China
-
Shanghai, China, 200032
-
Shanghai, China, 200127
-
Shanghai, China, 200233
-
Tianjin, China, 300000
-
-
Jiangsu
-
Nanjing, Jiangsu, China
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
-
-
-
-
-
Hong Kong, Hong Kong
-
-
New Territories
-
Shatin, New Territories, Hong Kong
-
-
-
-
West Java
-
Bandung, West Java, Indonesia, 40161
-
-
-
-
-
Incheon, Korea, Republic of, 405-760
-
Seoul, Korea, Republic of, 137-701
-
Seoul, Korea, Republic of, 150-713
-
Seoul, Korea, Republic of, 420-717
-
-
Kyonggi-do
-
Uijeongbu, Kyonggi-do, Korea, Republic of, 480-130
-
-
-
-
-
Terengganu, Malaysia, 20400
-
-
Sarawak
-
Kuching, Sarawak, Malaysia, 93400
-
-
-
-
-
Kaoshiung, Taiwan, 813
-
Tainan, Taiwan, 70428
-
Taipei, Taiwan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Hospitalized males or females >/= 18 years of age
- Expected duration of treatment with intravenous antibiotics in hospital is anticipated to be >/= 3 full days but not exceeding 14 days
- Ability to provide written informed consent
- Confirmed or suspected intra abdominal infection through surgical procedure or Radiological evidence. For suspected intra abdominal infection, The patient must be scheduled for a surgical procedure
Exclusion Criteria:
- Known hypersensitivity to fluoroquinolones, or other quinolones, and/or to beta lactams antibiotic drugs, or metronidazole or any of the excipients. History of tendon disease/disorder related to quinolone treatment
- Known congenital or documented acquired QT prolongation; uncorrected hypokalemia; clinically relevant bradycardia; clinically relevant heart failure with reduced left ventricular ejection fraction; previous history of symptomatic arrhythmias. Concomitant use of any of the following drugs, reported to increase the QT interval:
- Known severe end stage liver disease (Child Pugh C)
- Systemic antibacterial therapy for more than 24 h within 7 days of enrollment
- Indwelling peritoneal catheter, Pre existing ascites and presumed spontaneous bacterial peritonitis
- All pancreatic processes including pancreatic sepsis, peripancreatic sepsis, or an intra abdominal infection secondary to pancreatitis
- Traumatic perforation of the upper gastrointestinal tract (stomach, duodenum) or perforated peptic ulcer if duration of perforation is < 24 h or if operated on within 24 h of perforation
- Traumatic perforation of the small or large bowel if duration of perforation is < 12 h or if operated on within 12 h of perforation
- Transmural necrosis of the intestine due to acute embolic, thrombotic, or obstructive occlusions
- Acute cholecystitis with infection confined to the gallbladder unless there is evidence of an abscess or necrotic tissue or purulent exudate surrounding the gallbladder indicating a transition of bacteria and the inflammatory process into the abdominal cavity
- Early acute or suppurative, nonperforated appendicitis unless there is evidence of an abscess or peritoneal fluid containing leukocytes and micro organisms suggestive of regional contamination
- Infections originating from the female genital tract. Perinephric infections
- Severe, life threatening disease with a life expectancy of < 48 h or APS and APACHE scores of > 35, Known rapidly fatal underlying disease (death expected within 6 months)
- Neutropenia (neutrophil count < 1,000/microliter) caused by immunosuppressive therapy or malignancy
- Patients known to have AIDS or HIV seropositives who are receiving HAART
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 2
|
Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
|
Experimental: Arm 1
|
Moxifloxacin 400 mg every 24 h
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Response
Time Frame: After 10-14 days of treatment
|
After 10-14 days of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical and bacteriological response
Time Frame: During 3-5days of treatment
|
During 3-5days of treatment
|
Bacteriological and radiological response
Time Frame: After 10-14 days of treatment
|
After 10-14 days of treatment
|
Clinical response at the TOC visit in patients with bacteriological proven intra abdominal infection
Time Frame: After 10-14 days of treatment
|
After 10-14 days of treatment
|
Mortality attributable to intra abdominal infection
Time Frame: 13-28 days
|
13-28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2005
Primary Completion (Actual)
December 1, 2006
Study Completion (Actual)
January 1, 2007
Study Registration Dates
First Submitted
October 7, 2008
First Submitted That Met QC Criteria
October 7, 2008
First Posted (Estimate)
October 8, 2008
Study Record Updates
Last Update Posted (Estimate)
December 18, 2014
Last Update Submitted That Met QC Criteria
December 17, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Infections
- Communicable Diseases
- Intraabdominal Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptives, Oral
- Contraceptive Agents, Female
- Antiprotozoal Agents
- Antiparasitic Agents
- Moxifloxacin
- Metronidazole
- Ceftriaxone
- Norgestimate, ethinyl estradiol drug combination
Other Study ID Numbers
- 11647
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection, Intra-abdominal
-
University of BolognaIRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedIntra-Abdominal InfectionItaly
-
PfizerCompletedComplicated Intra-abdominal InfectionJapan
-
Cubist Pharmaceuticals LLCCompletedComplicated Intra-abdominal InfectionUnited States, Argentina, Serbia, Georgia, Russian Federation
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedComplicated Intra-Abdominal InfectionGreece
-
Iterum Therapeutics, International LimitedCompletedIntra Abdominal InfectionsUnited States, Bulgaria, Estonia, Georgia, Hungary, Latvia, Poland
-
Merck Sharp & Dohme LLCCompletedComplicated Intra-Abdominal InfectionBrazil, Hungary, United States, Lithuania, Malaysia, Mexico, Romania, Russian Federation, South Africa, Spain, Turkey, Ukraine
-
Merck Sharp & Dohme LLCCompletedIntra-abdominal Infection | Complicated Intra-abdominal Infection
-
Merck Sharp & Dohme LLCCompletedComplicated Intra-abdominal Infection
-
Kaohsiung Medical University Chung-Ho Memorial...CompletedIntra-abdominal InfectionTaiwan
Clinical Trials on Ceftriaxone + Metronidazole
-
Merck Sharp & Dohme LLCCompletedComplicated Intra-abdominal Infection
-
Merck Sharp & Dohme LLCCompletedSurgical Site Infection | Infection
-
HaEmek Medical Center, IsraelCompletedComplicated AppendicitisIsrael
-
PfizerCompletedIntra-abdominal InfectionsJapan
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedCholecystitis | Appendicitis | Diverticulitis | Intra-Abdominal Abscess | Intra-Abdominal Infection | PeritonitisItaly, Spain, China, France, Switzerland, Australia, Denmark, Finland, Germany, Greece, Hong Kong, India, Philippines, Portugal, Saudi Arabia, South Africa, Taiwan, Turkey, United Kingdom
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedCross Infection | Cholecystitis | Appendicitis | Diverticulitis | PeritonitisUnited States, Canada, Chile, Argentina, Brazil, Mexico
-
Merck Sharp & Dohme LLCCompleted
-
McMaster Children's HospitalNot yet recruiting
-
PfizerWithdrawnCommunity Acquired Bacterial Pneumonia | Complicated Intra-Abdominal Infection
-
Wyeth is now a wholly owned subsidiary of PfizerWithdrawnCommunity Acquired Bacterial Pneumonia | Complicated Intra-Abdominal Infection